Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Outlook Therapeutics Stock (NASDAQ: OTLK) stock price, news, charts, stock research, profile.
Day Range1.140 - 1.190 | 52 Wk Range0.684 - 2.120 | Open / Close1.190 / - | Float / Outstanding180.713M / 256.667M |
Vol / Avg.77.384K / 497.016K | Mkt Cap299.017M | P/E- | 50d Avg. Price1.050 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float180.713M | EPS-0.310 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-13 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.060 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV) and Precigen (NASDAQ:PGEN).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Friday, January 6, 2023. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 329.18% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.165 last updated Today at January 31, 2023 at 5:59 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q1 earnings are confirmed for Monday, February 13, 2023.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.